Breaking News, Collaborations & Alliances

Samsung Biologics, STCube Ink Cancer Drug Deal

Enter into development and manufacturing agreement for novel target anticancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung Biologics and STCube have formed a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate.   Under the agreement, Samsung Biologics will offer a wide range of services from cell line development, process development, manufacturing of non-clinical and clinical material, to IND submission for STCube.   STCube is an innovation-driven biopharmaceutical company developing breakthrough cancer therapies with its cutting-edge research. STCub...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters